Literature DB >> 19941841

Cholinesterase inhibitors and memory.

Giancarlo Pepeu1, Maria Grazia Giovannini.   

Abstract

A consensus exists that cholinesterase inhibitors (ChEIs) are efficacious for mild to moderate Alzheimer's Disease (AD). Unfortunately, the number of non-responders is large and the therapeutic effect is usually short-lasting. In experimental animals, ChEIs exert three main actions: inhibit cholinesterase (ChE), increase extracellular levels of brain acetylcholine (ACh), improve cognitive processes, particularly when disrupted in models of AD. In this overview we shall deal with the cognitive processes that are improved by ChEI treatment because they depend on the integrity of brain cholinergic pathways and their activation. The role of cholinergic system in cognition can be investigated using different approaches. Microdialysis experiments demonstrate the involvement of the cholinergic system in attention, working, spatial and explicit memory, information encoding, sensory-motor gating, skill learning. No involvement in long-term memory has yet been demonstrated. Conversely, memory consolidation is facilitated by low cholinergic activity. Experiments on healthy human subjects, notwithstanding caveats concerning age, dose, and different memory tests, confirm the findings of animal experiments and demonstrate that stimulation of the cholinergic system facilitates attention, stimulus detection, perceptual processing and information encoding. It is not clear whether information retrieval may be improved but memory consolidation is reduced by cholinergic activation. ChEI effects in AD patients have been extensively investigated using rating scales that assess cognitive and behavioural responses. Few attempts have been made to identify which scale items respond better to ChEIs and therefore, presumably, depend on the activity of the cholinergic system. Improvement in attention and executive functions, communication, expressive language and mood stability have been reported. Memory consolidation and retrieval may be impaired by high ACh levels. Therefore, considering that in AD the degeneration of the cholinergic system is associated with alteration of other neurotransmitter systems and a diffuse synaptic loss, a limited efficacy of ChEIs on memory processes should be expected. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19941841     DOI: 10.1016/j.cbi.2009.11.018

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  41 in total

1.  The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice.

Authors:  Derek S Wilkinson; Thomas J Gould
Journal:  Behav Brain Res       Date:  2011-04-14       Impact factor: 3.332

Review 2.  Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis.

Authors:  Siddhartha Mondragón-Rodríguez; Gustavo Basurto-Islas; Hyoung-gon Lee; George Perry; Xiongwei Zhu; Rudy J Castellani; Mark A Smith
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

3.  Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats.

Authors:  R B Gibbs; A M Chipman; R Hammond; D Nelson
Journal:  Horm Behav       Date:  2011-08-26       Impact factor: 3.587

4.  Long-term methionine exposure induces memory impairment on inhibitory avoidance task and alters acetylcholinesterase activity and expression in zebrafish (Danio rerio).

Authors:  Fernanda Cenci Vuaden; Luiz Eduardo B Savio; Angelo L Piato; Talita C Pereira; Mônica R Vianna; Maurício R Bogo; Carla D Bonan; Angela T S Wyse
Journal:  Neurochem Res       Date:  2012-03-22       Impact factor: 3.996

5.  Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment.

Authors:  Wenjun Li; Piero G Antuono; Chunming Xie; Gang Chen; Jennifer L Jones; B Douglas Ward; Malgorzata B Franczak; Joseph S Goveas; Shi-Jiang Li
Journal:  Neuroimage       Date:  2012-01-08       Impact factor: 6.556

6.  Oxidative insults to neurons and synapse are prevented by aged garlic extract and S-allyl-L-cysteine treatment in the neuronal culture and APP-Tg mouse model.

Authors:  Balmiki Ray; Neelima B Chauhan; Debomoy K Lahiri
Journal:  J Neurochem       Date:  2011-03-14       Impact factor: 5.372

7.  Brain tissue modifications induced by cholinergic therapy in Alzheimer's disease.

Authors:  Marco Bozzali; Geoff J M Parker; Barbara Spanò; Laura Serra; Giovanni Giulietti; Roberta Perri; Giuseppe Magnani; Camillo Marra; Maria G Vita; Carlo Caltagirone; Mara Cercignani
Journal:  Hum Brain Mapp       Date:  2012-06-19       Impact factor: 5.038

8.  In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.

Authors:  Altaf S Darvesh; Richard T Carroll; Werner J Geldenhuys; Gary A Gudelsky; Jochen Klein; Charles K Meshul; Cornelis J Van der Schyf
Journal:  Expert Opin Drug Discov       Date:  2011-02       Impact factor: 6.098

Review 9.  Reassessment of the role of the central cholinergic system.

Authors:  Anna Hrabovska; Eric Krejci
Journal:  J Mol Neurosci       Date:  2013-11-10       Impact factor: 3.444

10.  Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans.

Authors:  E L Theunissen; P Heckman; E B de Sousa Fernandes Perna; K P C Kuypers; A Sambeth; A Blokland; J Prickaerts; S W Toennes; J G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2014-07-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.